NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin

Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300

(2010) Mitsunori Harada et al.   CANCER SCIENCE

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Doxorubicinolone Formation and Efflux: A Salvage Pathway against Epirubicin Accumulation in Human Heart

(2009) E. Salvatorelli et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre Study

(2008) Evandro de Azambuja et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

(2008) M. Martin et al.   JNCI-Journal of the National Cancer Institute

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE